(MedPage Today) — SAN FRANCISCO — Delivering on durability, the Esprit drug-eluting resorbable scaffold (DRS) maintained superior outcomes 3 years into the LIFE-BTK trial.
For infrapopliteal artery disease causing chronic limb-threatening…
Source link : https://www.medpagetoday.com/meetingcoverage/tct/118171
Author :
Publish date : 2025-10-27 20:26:00
Copyright for syndicated content belongs to the linked Source.
